Brief: Rallybio Announces Positive Data For RLYB116 Phase 1 Study
17/02/2026 13:37
Feb 17 (Reuters) - Rallybio Corp RLYB.O: RALLYBIO ANNOUNCES POSITIVE DATA FOR RLYB116 PHASE 1 STUDY DEMONSTRATING COMPLETE AND SUSTAINED INHIBITION OF TERMINAL COMPLEMENT RALLYBIO CORP - RLYB116 PHASE 2 TRIAL PLANNED FOR 2H 2026 WITH POTENTIAL FOR TOPLINE DATA IN 2027 RALLYBIO CORP - RLYB116 DOSES WELL TOLERATED WITH NO GI SIDE EFFECTS Source text: ID:nBw2q7DYLa Further company coverage: RLYB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx